SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 9, nr. 4, 2014

ISSN 1841-9038  |  e-ISSN 2069-6116
ISSN-L 1841-9038
CNCSIS - CMR - B+

More Indications Approved and Safety News for Dabigatran Etexilate

For more than 50 years, the only oral anticoagulation therapy available was with vitamin K antagonists. The difficulties to monitor, the instability against other drugs or aliments and the risk of this therapy are well known and studied.

In the last years new families of oral anticoagulants were developed, known today as New Oral Anticoagulants (NOAC). The first one clinical ly studied was ximelagatran. Its hepatic toxicity stopped it for development. The next oral anticoagulants who accomplished important clinical studies were dabigatran, apixaban, rivaroxaban and edoxaban. From these, dabigatran is a direct thrombin inhibitor, while the other three are factor Xa inhibitors. However, all four NOAC are studied to date in similar clinical conditions.

In this paper we will show some clinical results and some adverse effects for the direct thrombin inhibitor of the group, dabigatran etexilate.

Full text | PDF